Bill has joined the board of directors as an independent member at Clearside Biomedical, a Georgia-based company developing therapeutics to treat sight threatening diseases through a proprietary ocular microinjection platform.

Bill is a seasoned executive with more than 25 years of experience in the industry at leading companies in the specialty pharma space. It was most recently announced by the Merz Pharma Group that Bill was appointed CEO of the US holding company, Merz Inc. Prior to joining Merz, he served as the president of Stiefel, where he spearheaded multiple acquisitions, triple digit revenue growth, and led the global integration of Stiefel into GlaxoSmithKline. He also has held multiple senior executive roles within Allergan, Inc., concluding as vice president of the U.S. skincare business.

Bill holds a bachelor of arts degree from Bucknell University in Lewisburg, Penn., as well as an MBA from Pepperdine University’s Graziadio School of Business and Management.

Dr. Mark Tilley has been named by  Fusion UV Systems as vice president for business development.

Dr. Tilley

Before joining Fusion, Mark was president and CEO of Unidym, a California-based company that develops electronic applications of carbon-nanotube based inks and films.

David Harbourne, president of Fusion UV Systems, said, “We are very pleased that Dr. Tilley will be joining Fusion. His experience, education and commitment to innovation are a perfect match for Fusion. Dr Tilley’s experience in the UV markets and his passion for innovation are precisely the characteristics we have been looking for and we are anxious for him to be on board and contributing to Fusion’s global leadership.” continue

Gunter was recently named president of SVTC Solar of SVTC Technologies, an innovation partner for accelerating nanotechnology development and commercialization. In his new role, Gunter will focus on growing the company’s global solar business as well as defining, establishing and overseeing the photovoltaic manufacturing development facility. SVTC Solar provides access to manufacturing and technology development services for the entire value chain of solar module manufacturing, qualification, test and financing.

“Gunter has a strong track record of leadership and outstanding results during his career in both the solar and semiconductor industries,” said Bert Bruggeman, chief executive officer of SVTC Technologies. “His experience in delivering new products in record time is noteworthy, and as leader of SVTC Solar, he will play an important role in advancing new ideas for next generation photovoltaic manufacturing.” continue

Terry has been appointed by KCAS, LLC, a leading bioanalytical contract research organization (CRO), as chief executive officer.

“It is an honor to take on this role at KCAS,” Dr. Osborn said. “KCAS continues to make great progress. I’m excited about the opportunity to execute our vision of strategic growth while continuing to provide the best customer service to our clients.”

Dr. Osborn continues, “KCAS has a proud history. Our scientific credibility is built on the important contributions we’ve made to our clients’ research for over thirty years. No regulatory agency has ever rejected a study based on our data. My goal is to continue building on that reputation and drive growth in our small molecule, large molecule and alkaline hematin lines of business.” continue

Kathryn has been appointed vice president of business development at PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing novel drugs to treat diabetes, metabolic disease and cardiovascular disease. Kathryn has more than 20 years of experience in international business development with a proven track record of negotiating deals and partnerships.

“Kathryn’s extensive deal making experience in partnering proprietary products and next generation biopharmaceuticals will position PhaseBio for long term growth,” said Christopher Prior, Ph.D., CEO of PhaseBio. continue

Natasha was recently appointed to the position of vice president, corporate development, at Seattle Genetics, Inc. Natasha brings ten years of experience in business and corporate development, including in-licensing, out-licensing and mergers and acquisitions.

“Natasha has broad experience in a variety of biotechnology and pharmaceutical business development transactions combined with demonstrated leadership acumen,” said Eric L. Dobmeier, chief business officer of Seattle Genetics. continue

Doug is the new vice president of global marketing at Agendia, a world leader in molecular cancer diagnostics, it was recently announced. Doug will manage all strategic and tactical marketing activities.

“As Agendia grows it is vital that we continually seek out the brightest and most innovative minds in the industry to add to our already stellar team,” said Dr. Bernhard Sixt, CEO and co-founder of Agendia. “We have done just that with the hiring of  Doug, who will help us make more people aware of Agendia’s truly revolutionary technology worldwide.”

Doug brings a wealth of leadership experience in medical and pharmaceutical product marketing at companies including Coherent Medical, Allergan and SenoRx. Most recently, he served as vice president of marketing at Vertos Medical. In his eight years at Irvine-based SenoRx, Bradley led the company’s marketing activities from its infancy. In this role, Doug became intimately familiar with medical devices for the diagnosis and treatment of breast cancer. During his time at SenoRx, they received the “Technology Fast 50″ award from Deloitte & Touch in 2006, 2007 and 2008. He holds a bachelor of science degree in microbiology from the University of Oklahoma and an MBA from Pepperdine University.

Douglas is now part-owner of Altair Instruments, a healthcare company and premier manufacturer of crystal-free microdermabarsion products. The corporate change of ownership will be shared with Brendalie Acosta, who will also serve as the company’s new president.  Douglas will serve as the new head of technology development and manufacturing at Altair.

Altair Instruments Inc. is a healthcare and beauty company that markets both the Diamondtome™ and Newapeel® Aesthetic Exfoliation Systems.   The company has numerous U.S patents and trademarks including bothy utility and method patents on its skin resurfacing and exfoliation products.  The company has extended this intellectual property protection to over two dozen countries worldwide. continue

Sam has accepted a position with Conceptus, Inc., developer of the Essure® procedure, a non-surgical permanent birth control method. Sam, a healthcare industry veteran, will take on the newly created position of executive vice president of marketing, effective immediately.

Sam joins Conceptus with nearly 30 years experience in global pharmaceutical and medical device marketing, including new product commercialization, consumer brand creation and management, and strategy development and implementation.

Most recently, Sam was with Bayer Healthcare Pharmaceuticals from 2006 to 2010. For much of this time, he was director of women’s healthcare, consumer marketing, responsible for contraceptive products, among others.  Medical Marketing and Media magazine recognized him as a “top six marketer” in 2009 based on the success of the launch of YAZ®. continue

Darren has been appointed by Seattle Genetics, Inc. as vice president of managed markets. Darren has over 20 years of sales and marketing experience, including senior managed markets roles in leading biotechnology and pharmaceutical companies.

“Darren has extensive oncology experience from senior sales and marketing positions at Amgen and Alexion,” said Bruce J. Seeley, executive vice president, commercial, “and brings to Seattle Genetics an important understanding of managed markets and the U.S. healthcare system that will be key to the launch of brentuximab vedotin.” continue